Undermining Value-Based Purchasing — Lessons from the Pharmaceutical Industry

Although it's not yet clear how health care providers will respond to value-based payment models, an examination of pharmaceutical industry practices can provide insights into problems that may arise — and practices to avoid. In 2015, the U.S. Department of Health and Human Services announced a...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 375; no. 21; pp. 2013 - 2015
Main Authors: Dafny, Leemore S, Ody, Christopher J, Schmitt, Matthew A
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 24.11.2016
Subjects:
ISSN:0028-4793, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although it's not yet clear how health care providers will respond to value-based payment models, an examination of pharmaceutical industry practices can provide insights into problems that may arise — and practices to avoid. In 2015, the U.S. Department of Health and Human Services announced a goal of linking at least 50% of Medicare spending to value-based payment models such as accountable care organizations. 1 Health care providers are now scrambling to reorganize in a way that delivers value while preserving or enhancing commercial success. Although it’s not yet clear how providers will respond to value-based payment models, an examination of pharmaceutical industry practices can provide insights into problems that may arise — and practices to avoid. Value-based plan design — a term that describes payers’ efforts to align consumer cost sharing with the value . . .
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Commentary-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMp1607378